期刊文献+

THOR在胃癌细胞中的表达及对胃癌细胞干性的影响 被引量:1

Expression of THOR in gastric cancer cells and its influence on stemness of gastric cancer cells
下载PDF
导出
摘要 目的:探究睾丸相关的高保守的致癌长链非编码RNA(THOR)在胃癌细胞中的表达及对胃癌细胞干性的影响。方法:收集徐州医科大学附属医院36对胃癌及癌旁正常组织标本,进行相关细胞培养、细胞活力测定、实时荧光定量PCR、慢病毒包和稳定的细胞株构建、mRNA稳定性分析、细胞球形形成分析、RNA测序分析、ALDH1活动分析,并对实验数据进行对比分析。结果:RNA测序分析发现胃癌组织中THOR水平较癌旁正常组织明显上调(P<0.01)。随着THOR的稳定敲除,胃癌细胞中的干性标志物(ALDH1,Nanog,Oct1,Oct 2,Oct 4,SOX2,SOX9,CD44)的表达显著降低(均P<0.01)。并且THOR的敲除降低了胃癌细胞形成球状体的能力,表现为球体尺寸变小和数量减少(P<0.01)。结论:THOR在胃癌细胞中的表达显著升高,敲除THOR可以降低胃癌细胞的干性。THOR与胃癌细胞中的干性标志物之间具有明显的作用关系,THOR可能是胃癌治疗的一个新的靶点。 Objective:To investigate the expression of testis-associated highly-conserved oncogenic long non-coding RNA(THOR)in gastric cancer cells and its influence on the stemness of gastric cancer cells.Methods:36 pairs of the specimens of gastric cancer tissue and normal tissues adjacent to cancer were collected from Affiliated Hospital of Xuzhou Medical University.Cell culture,cell viability test,real-time fluorescence quantitative PCR,construction of lentivirus envelope and stable cell line,analysis of mRNA stability,analysis of cell spheroid formation,RNA sequencing analysis,ALDH1 activity analysis were carried out,and the experimental data were compared and analyzed eventually.Results:RNA sequencing showed that the level of THOR in gastric cancer tissue was significantly higher than that in normal tissues(P<0.01).With the stable knockout of THOR,the expression of stemness markers including ALDH1,Nanog,Oct1,Oct 2,Oct 4,Sox2,Sox9 and CD44 in gastric cancer cells decreased significantly(P<0.01).In addition,the knockout of THOR decreased the ability of gastric cancer cells to form globules,which showed that the size and number of globules decreased(P<0.01).Conclusion:The expression of THOR in gastric cancer cells significantly increases,and the knockout of THOR can reduce the stemness of gastric cancer cells.There is a significant relationship between THOR and the stemness markers in gastric cancer cells,therefore THOR may be a new target for the treatment of gastric cancer.
作者 许雁晗 宋虎 宋军 宗启言 邹钰 李想 辛科 Xu Yanhan;Song Hu;Song Jun;Zong Qiyan;Zou Yu;Li Xiang;Xin Ke(School of Clinical Medicine,Xuzhou Medical University,Xuzhou,Jiangsu 221004,China;General Surgery,Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu 221002,China;Institute of Digestive Diseases,Xuzhou Medical University,Xuzhou,Jiangsu 221002,China)
出处 《现代临床医学》 2020年第4期249-252,共4页 Journal of Modern Clinical Medicine
基金 基础医学国家级实验教学示范中心(徐州医科大学)资助项目(201810313065X)。
关键词 长链非编码RNA THOR 胃癌细胞 干性 lncRNA THOR stemness gastric cancer cells
  • 相关文献

参考文献3

二级参考文献63

  • 1钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 2Moiseyenko VM,Ajani JA,Tjulandin SA,et al.Final results of a randomized controlled phase Ⅲ trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F)to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2005,23:Abstract 4002. 被引量:1
  • 3Al-Batran S,Hartmann J,Probst S,et al.A randomized phase Ⅲ trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil,leucovorin and oxaliplatin (FLO) versus fluorouracil,leucovorin and cisplatin (FLP)[J].J Clin Onc,Proc Am Soc Clin Oncol,2006,24:Abstract 4016. 被引量:1
  • 4Bugat R.Irinotecan in the treatment of gastric cancer[J].Ann Oncol,2003,14(Suppl 2):37 -40. 被引量:1
  • 5Bouche O,Raoul JL,Bonnetain F,et al.Randomized multicenter phase Ⅱ trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),LV5FU2 plus cisplatin,or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer:a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803[ J].J Clin Oncol,2004,22 (21):4319-4328. 被引量:1
  • 6Fazio N,Zampino G,Nol F,et al.Irinotecan combined with in fusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemo therapy[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4146a. 被引量:1
  • 7Peeters M,Van Laethem JL,Baert F,et al.Phase Ⅱ study of irinotecan+ 5FU/FA for patients with previously treated ad vanced gastric cancer[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4076a. 被引量:1
  • 8Bamias A,Papamichael D,Syrigos K,et al.Phase Ⅱ study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer[J].J Chemother,2003,15(3):275 -281. 被引量:1
  • 9Giuliani F,Maiello E,Molica S,et al.Irinotecan (CPT-11)and Mitomycin-C (MMC) as second-line treatment in advanced gastric cancer patients.A phase Ⅱ study of the Gruppo Oncologico dell Italia Meridionale (GOIM)[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4235. 被引量:1
  • 10Shah M A,Ramanathan RK,Ilson D,et al.Final results of a multicenter phase Ⅱ study of irinotecan (CPT),cisplatin (CIS),and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2006,24 (18S):Abstract 4020. 被引量:1

共引文献315

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部